icon clinical research (u.k.) no. 4 limited
icon clinical research (u.k.) no. 4 limited Company Information
Company Number
03628305
Website
www.medpass.orgRegistered Address
1 more london place, london, SE1 2AF
Industry
Other business support service activities n.e.c.
Telephone
01386830601
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
icon clinical research (u.k.) no. 6 limited 100%
icon clinical research (u.k.) no. 4 limited Estimated Valuation
Pomanda estimates the enterprise value of ICON CLINICAL RESEARCH (U.K.) NO. 4 LIMITED at £0 based on a Turnover of £0 and 0.53x industry multiple (adjusted for size and gross margin).
icon clinical research (u.k.) no. 4 limited Estimated Valuation
Pomanda estimates the enterprise value of ICON CLINICAL RESEARCH (U.K.) NO. 4 LIMITED at £1.1m based on an EBITDA of £257.4k and a 4.16x industry multiple (adjusted for size and gross margin).
icon clinical research (u.k.) no. 4 limited Estimated Valuation
Pomanda estimates the enterprise value of ICON CLINICAL RESEARCH (U.K.) NO. 4 LIMITED at £3m based on Net Assets of £5.8m and 0.52x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Icon Clinical Research (u.k.) No. 4 Limited Overview
Icon Clinical Research (u.k.) No. 4 Limited is a live company located in london, SE1 2AF with a Companies House number of 03628305. It operates in the other business support service activities n.e.c. sector, SIC Code 82990. Founded in September 1998, it's largest shareholder is icon clinical research (u.k.) no. 6 limited with a 100% stake. Icon Clinical Research (u.k.) No. 4 Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Icon Clinical Research (u.k.) No. 4 Limited Health Check
Pomanda's financial health check has awarded Icon Clinical Research (U.K.) No. 4 Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 3 areas for improvement. Company Health Check FAQs
1 Strong
0 Regular
3 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Icon Clinical Research (u.k.) No. 4 Limited
- - Industry AVG
Growth
3 year (CAGR) sales growth of -100%, show it is growing at a slower rate (3%)
- - Icon Clinical Research (u.k.) No. 4 Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Icon Clinical Research (u.k.) No. 4 Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Icon Clinical Research (u.k.) No. 4 Limited
- - Industry AVG
Employees
with 3 employees, this is below the industry average (24)
- - Icon Clinical Research (u.k.) No. 4 Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- - Icon Clinical Research (u.k.) No. 4 Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- - Icon Clinical Research (u.k.) No. 4 Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Icon Clinical Research (u.k.) No. 4 Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Icon Clinical Research (u.k.) No. 4 Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Icon Clinical Research (u.k.) No. 4 Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 1 weeks, this is less cash available to meet short term requirements (24 weeks)
- - Icon Clinical Research (u.k.) No. 4 Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 0.2%, this is a lower level of debt than the average (63.7%)
- - Icon Clinical Research (u.k.) No. 4 Limited
- - Industry AVG
ICON CLINICAL RESEARCH (U.K.) NO. 4 LIMITED financials
Icon Clinical Research (U.K.) No. 4 Limited's latest turnover from December 2022 is 0 and the company has net assets of £5.8 million. According to their latest financial statements, Icon Clinical Research (U.K.) No. 4 Limited has 3 employees and maintains cash reserves of £335 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 0 | 117,294 | 751,187 | 810,730 | ||||||||||
| Other Income Or Grants | 0 | 0 | 0 | 0 | ||||||||||
| Cost Of Sales | 0 | 0 | 522,535 | 584,720 | ||||||||||
| Gross Profit | 0 | 117,294 | 228,652 | 226,010 | ||||||||||
| Admin Expenses | -257,380 | 125,266 | 226,624 | 212,386 | ||||||||||
| Operating Profit | 257,380 | -7,972 | 2,028 | 13,624 | ||||||||||
| Interest Payable | 0 | 0 | 0 | 0 | ||||||||||
| Interest Receivable | 16,410 | 2,975 | 0 | 21 | ||||||||||
| Pre-Tax Profit | 273,790 | 5,161,241 | 2,028 | 13,645 | ||||||||||
| Tax | -52,114 | 836 | -338 | -2,582 | ||||||||||
| Profit After Tax | 221,676 | 5,162,077 | 1,690 | 11,063 | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | ||||||||||
| Retained Profit | 221,676 | 5,162,077 | 1,690 | 11,063 | ||||||||||
| Employee Costs | 0 | 0 | 600,692 | 672,124 | ||||||||||
| Number Of Employees | 3 | 3 | 7 | 9 | 12 | 12 | 14 | 13 | ||||||
| EBITDA* | 257,380 | -7,972 | 2,028 | 13,624 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 11,500 | 17,586 | 672 | 0 | 0 | 0 | 0 | 0 | 374 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 879 | 879 | 879 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 879 | 879 | 879 | 11,500 | 17,586 | 672 | 0 | 0 | 0 | 0 | 0 | 374 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 113,704 | 195,978 | 221,543 | 220,463 | 246,412 | 196,241 | 118,977 | 174,033 | 108,152 | 120,777 | 86,891 |
| Group Debtors | 5,817,010 | 5,543,007 | 305,901 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 694 | 7,995 | 14,208 | 9,024 | 9,375 | 7,753 | 14,285 | 8,517 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 335 | 43,355 | 141,335 | 343,166 | 377,201 | 2,016,423 | 1,672,126 | 1,274,854 | 1,092,527 | 958,494 | 666,913 | 455,494 | 276,335 | 155,957 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 5,818,039 | 5,594,357 | 461,444 | 465,894 | 582,554 | 2,245,719 | 1,906,874 | 1,529,783 | 1,288,768 | 1,077,471 | 840,946 | 563,646 | 397,112 | 242,848 |
| total assets | 5,818,039 | 5,594,357 | 462,323 | 466,773 | 583,433 | 2,257,219 | 1,924,460 | 1,530,455 | 1,288,768 | 1,077,471 | 840,946 | 563,646 | 397,112 | 243,222 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 15,124 | 84,327 | 116,196 | 101,555 | 112,385 | 193,174 | 226,458 | 266,383 | 241,544 | 237,769 | 182,135 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 11,425 | 9,419 | 39,462 | 30,478 | 88,998 | 116,298 | 126,875 | 124,375 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 11,425 | 9,419 | 39,462 | 45,602 | 173,325 | 232,494 | 228,430 | 236,760 | 193,174 | 226,458 | 266,383 | 241,544 | 237,769 | 182,135 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 11,425 | 9,419 | 39,462 | 45,602 | 173,325 | 232,494 | 228,430 | 236,791 | 193,174 | 226,458 | 266,383 | 241,544 | 237,769 | 182,135 |
| net assets | 5,806,614 | 5,584,938 | 422,861 | 421,171 | 410,108 | 2,024,725 | 1,696,030 | 1,293,664 | 1,095,594 | 851,013 | 574,563 | 322,102 | 159,343 | 61,087 |
| total shareholders funds | 5,806,614 | 5,584,938 | 422,861 | 421,171 | 410,108 | 2,024,725 | 1,696,030 | 1,293,664 | 1,095,594 | 851,013 | 574,563 | 322,102 | 159,343 | 61,087 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 257,380 | -7,972 | 2,028 | 13,624 | ||||||||||
| Depreciation | 0 | 0 | 0 | 0 | 5,750 | 6,086 | 6,086 | 336 | 0 | 0 | 0 | 0 | 374 | 563 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Tax | -52,114 | 836 | -338 | -2,582 | ||||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 266,702 | 5,230,893 | 197,381 | -82,625 | -23,943 | -5,452 | -20,181 | 58,688 | 77,264 | -55,056 | 65,881 | -12,625 | 33,886 | 86,891 |
| Creditors | 0 | 0 | -15,124 | -69,203 | -31,869 | 14,641 | -10,830 | -80,789 | -33,284 | -39,925 | 24,839 | 3,775 | 55,634 | 182,135 |
| Accruals and Deferred Income | 2,006 | -30,043 | 8,984 | -58,520 | -27,300 | -10,577 | 2,500 | 124,375 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | -31 | 31 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -59,430 | -5,268,072 | -201,831 | -34,056 | ||||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | -879 | 0 | 0 | 879 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 16,410 | 2,975 | 0 | 21 | ||||||||||
| cash flow from financing | 16,410 | 2,975 | 0 | 21 | ||||||||||
| cash and cash equivalents | ||||||||||||||
| cash | -43,020 | -97,980 | -201,831 | -34,035 | -1,639,222 | 344,297 | 397,272 | 182,327 | 134,033 | 291,581 | 211,419 | 179,159 | 120,378 | 155,957 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -43,020 | -97,980 | -201,831 | -34,035 | -1,639,222 | 344,297 | 397,272 | 182,327 | 134,033 | 291,581 | 211,419 | 179,159 | 120,378 | 155,957 |
icon clinical research (u.k.) no. 4 limited Credit Report and Business Information
Icon Clinical Research (u.k.) No. 4 Limited Competitor Analysis
Perform a competitor analysis for icon clinical research (u.k.) no. 4 limited by selecting its closest rivals, whether from the ADMINISTRATIVE AND SUPPORT SERVICE ACTIVITIES sector, other mature companies, companies in SE1 area or any other competitors across 12 key performance metrics.
icon clinical research (u.k.) no. 4 limited Ownership
ICON CLINICAL RESEARCH (U.K.) NO. 4 LIMITED group structure
Icon Clinical Research (U.K.) No. 4 Limited has no subsidiary companies.
Ultimate parent company
ICON INVESTMENTS LTD
#0120551
2 parents
ICON CLINICAL RESEARCH (U.K.) NO. 4 LIMITED
03628305
icon clinical research (u.k.) no. 4 limited directors
Icon Clinical Research (U.K.) No. 4 Limited currently has 5 directors. The longest serving directors include Mr Brendan Harte (Jan 2020) and Mr Bryan O'Boyle (Jan 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Brendan Harte | United Kingdom | 59 years | Jan 2020 | - | Director |
| Mr Bryan O'Boyle | England | 41 years | Jan 2020 | - | Director |
| Mr Harvey Grove | England | 76 years | Jan 2020 | - | Director |
| Mr Simon Hollywood | 44 years | Oct 2023 | - | Director | |
| Emer Lyons | England | 46 years | Oct 2023 | - | Director |
P&L
December 2022turnover
0
-100%
operating profit
257.4k
-3329%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
5.8m
+0.04%
total assets
5.8m
+0.04%
cash
335
-0.99%
net assets
Total assets minus all liabilities
icon clinical research (u.k.) no. 4 limited company details
company number
03628305
Type
Private limited with Share Capital
industry
82990 - Other business support service activities n.e.c.
incorporation date
September 1998
age
26
incorporated
UK
accounts
Full Accounts
ultimate parent company
previous names
medpass international limited (April 2021)
last accounts submitted
December 2022
address
1 more london place, london, SE1 2AF
accountant
-
auditor
HAZLEWOODS LLP
icon clinical research (u.k.) no. 4 limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to icon clinical research (u.k.) no. 4 limited.
icon clinical research (u.k.) no. 4 limited Companies House Filings - See Documents
| date | description | view/download |
|---|
